Cain David 4

What Happened David Cain, a director and CMC member at Kazia Therapeutics (KZIA), received a board-approved award of 100,000 options over American Depositary Shares (ADSs) on January 8, 2026. The options were granted for no consideration (acquisition price $0.00), carry an exercise price of $9.10 per ADS, and expire on January 8, 2029. One-third of the options vest on January 8, 2027, with the remaining two-thirds vesting in equal yearly tranches thereafter.

Key Details

• Transaction date: 2026-01-08 (reported filing date: 2026-07-08).
• Transaction type/code: Award/Grant (A); derivative (options) — acquisition reported as $0.00.
• Instrument: 100,000 options over ADSs; exercise price $9.10 per ADS.
• Vesting: 1/3 on Jan 8, 2027; remaining 2/3 in equal annual tranches on anniversaries of that date.
• Expiration: Options expire Jan 8, 2029.
• Shares owned after transaction: not specified in the filing.
• Footnote: Exercise price reflects Australian tax considerations for resident participants under the issuer's employee share plan.
• Timeliness: Filing reported July 8, 2026 for a Jan 8, 2026 grant — appears late (Form 4s are normally due within two business days), which reduces near‑term transparency.

Context This was a grant of options (not an exercise or sale), so no shares were issued or sold immediately and no cash changed hands. The economic value to the insider depends on future vesting, the company’s ADS market price at exercise, and whether the options are exercised before the Jan 8, 2029 expiry. Grants are commonly part of compensation/retention programs and do not by themselves signal insider buying or selling.